Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EARS Auris Medical	$0.30	$2.88	$0.73 ▼ $6.60	$3.43M	1.17	3.10 million shs	830,271 shs
IBIO iBio	$0.84 +6.4%	$0.73	$0.56 ▼ $6.89	$16.55M	0.6	1.39 million shs	956,297 shs
MTNB Matinas Biopharma	$2.15 +0.9%	$1.10	$0.47 ▼ $5.20	$10.94M	1.32	446,739 shs	114,603 shs
TAOX Synaptogenix	$7.01 -8.4%	$0.00	$1.84 ▼ $11.98	$24.47M	1.87	427,979 shs	146,449 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EARS Auris Medical	0.00%	0.00%	0.00%	0.00%	-68.60%
IBIO iBio	0.00%	+6.72%	+7.90%	-3.30%	-61.03%
MTNB Matinas Biopharma	0.00%	-9.75%	+129.01%	+162.32%	+1,047.01%
TAOX Synaptogenix	0.00%	-8.93%	+764,999,900.00%	+764,999,900.00%	+764,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EARS Auris Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	1.8277 of 5 stars	3.5	0.0	0.0	0.0	2.5	0.0	0.6
MTNB Matinas Biopharma	0.688 of 5 stars	0.0	5.0	0.0	0.0	1.1	0.0	0.6
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EARS Auris Medical	0.00	N/A	N/A	N/A
IBIO iBio	3.00	Buy	$5.00	493.82% Upside
MTNB Matinas Biopharma	2.00	Hold	N/A	N/A
TAOX Synaptogenix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EARS, IBIO, TAOX, and MTNB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EARS Auris Medical	N/A	N/A	N/A	N/A	$1.57 per share	N/A
IBIO iBio	$375K	44.13	N/A	N/A	$1.41 per share	0.60
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	$4.43 per share	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EARS Auris Medical	-$8.75M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
MTNB Matinas Biopharma	-$22.94M	-$3.89	N/A	∞	N/A	N/A	-123.06%	-94.28%	N/A
TAOX Synaptogenix	-$12.77M	-$20.16	N/A	∞	N/A	N/A	-277.76%	-150.79%	N/A

Latest EARS, IBIO, TAOX, and MTNB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/15/2025	Q2 2025	TAOX Synaptogenix	N/A	-$11.26	N/A	-$11.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EARS Auris Medical	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EARS Auris Medical	N/A	3.83	3.83
IBIO iBio	0.05	1.76	1.76
MTNB Matinas Biopharma	N/A	5.53	5.53
TAOX Synaptogenix	N/A	20.52	20.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EARS Auris Medical	6.03%
IBIO iBio	7.90%
MTNB Matinas Biopharma	11.77%
TAOX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
EARS Auris Medical	N/A
IBIO iBio	0.58%
MTNB Matinas Biopharma	4.60%
TAOX Synaptogenix	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EARS Auris Medical	132,200	11.42 million	N/A	Not Optionable
IBIO iBio	100	19.66 million	9.82 million	N/A
MTNB Matinas Biopharma	30	5.09 million	4.60 million	N/A
TAOX Synaptogenix	4	3.49 million	3.39 million	N/A

EARS, IBIO, TAOX, and MTNB Headlines

Recent News About These Companies

Wall Street Zen Downgrades Synaptogenix (NASDAQ:TAOX) to Sell

August 19, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EARS, IBIO, TAOX, and MTNB Company Descriptions

Auris Medical NASDAQ:EARS

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

iBio NYSE:IBIO

$0.84 +0.05 (+6.45%)

Closing price 03:59 PM Eastern

Extended Trading

$0.84 0.00 (0.00%)

As of 04:04 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Matinas Biopharma NYSE:MTNB

$2.15 +0.02 (+0.75%)

As of 04:00 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Synaptogenix NASDAQ:TAOX

$7.01 -0.64 (-8.37%)

As of 03:45 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time